Boehringer Ingelheim to use PhoreMost's SITESEEKER platform in new collaboration

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, one of the world-leading pharmaceutical companies developing innovative therapies for diseases with unsatisfactory treatments.

Under the terms of the agreement, PhoreMost will receive an upfront payment and research funding together with downstream success-based milestones. Further financial terms are not disclosed.

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, towards disease-relevant pathways nominated by Boehringer Ingelheim.

Novel targets identified will be further validated and characterized by Boehringer Ingelheim as part of its internal Discovery Research pipeline. Boehringer Ingelheim’s Research program is active in the fields of immunology and respiratory diseases, cardiometabolic diseases, oncology research, and immuno-oncology, as well as diseases of the central nervous system.

The SITESEEKER platform is based on PhoreMost’s core proprietary protein interference, or ‘PROTEINi’, technology.

Using SITESEEKER, PhoreMost probes the entire proteome in a live cell environment for novel druggable targets linked to any chosen disease, using the vast 3-D shape diversity of natural protein fragment (sub-domain) libraries. This enables the systematic unmasking of cryptic druggable sites, directly linking them to useful therapeutic functions.

We are delighted that Boehringer Ingelheim has chosen to work with PhoreMost to enhance its drug discovery pipeline with attractive biological starting points. The collaboration is further recognition of the ability of PROTEINi and SITESEEKER to identify novel targets, and we look forward to working with the Boehringer Ingelheim team on these projects.

Dr Chris Torrance, CEO of PhoreMost

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    PhoreMost. (2020, January 07). Boehringer Ingelheim to use PhoreMost's SITESEEKER platform in new collaboration. News-Medical. Retrieved on July 19, 2024 from https://www.news-medical.net/news/20200107/Boehringer-Ingelheim-to-use-PhoreMosts-SITESEEKER-platform-in-new-collaboration.aspx.

  • MLA

    PhoreMost. "Boehringer Ingelheim to use PhoreMost's SITESEEKER platform in new collaboration". News-Medical. 19 July 2024. <https://www.news-medical.net/news/20200107/Boehringer-Ingelheim-to-use-PhoreMosts-SITESEEKER-platform-in-new-collaboration.aspx>.

  • Chicago

    PhoreMost. "Boehringer Ingelheim to use PhoreMost's SITESEEKER platform in new collaboration". News-Medical. https://www.news-medical.net/news/20200107/Boehringer-Ingelheim-to-use-PhoreMosts-SITESEEKER-platform-in-new-collaboration.aspx. (accessed July 19, 2024).

  • Harvard

    PhoreMost. 2020. Boehringer Ingelheim to use PhoreMost's SITESEEKER platform in new collaboration. News-Medical, viewed 19 July 2024, https://www.news-medical.net/news/20200107/Boehringer-Ingelheim-to-use-PhoreMosts-SITESEEKER-platform-in-new-collaboration.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PhoreMost and Oxford Biomedica collaborate to develop next-generation CAR-T cell therapies